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ABSTRACT In this review the distinct aspects of somatic cell reprogramming are discussed. The molecular mecha-
nisms of generation of induced pluripotent stem (iPS) cells from somatic cells via the introduction of transcrip-
tion factors into adult somatic cells are considered. Particular attention is focused on the generation of iPS cells 
without genome modifications via the introduction of the mRNA of transcription factors or the use of small mol-
ecules. Furthermore, the strategy of direct reprogramming of somatic cells omitting the generation of iPS cells is 
considered. The data concerning the differences between ES and iPS cells and the problem of epigenetic memory 
are also discussed. In conclusion, the possibility of using iPS cells in regenerative medicine is considered.
KEYWORDS reprogramming; iPS cells; ES cells; differentiation; transformation; pluripotency.
ABBREVIATIONS ESCs – embryonic stem cells; iPSCs – induced pluripotent stem cells; Chd1 – chromodomain 
helicase DNA-binding protein; BAF – rg/Brahma-associated factors; miRNA, miR – microRNA; TERRA – tel-
omeric-repeat-containing RNA; Cdkn – cyclin-dependent kinase inhibitor; VPA – valproic acid; siRNA – small 
interfering RNA; KMOS – Klf4, c-Myc, Oct4, Sox2; KOS – Klf4, Oct4, Sox2; LNOS – Lin28, Nanog, Oct4, Sox2; 
GSK-3 – glycogen synthase kinase 3; ROS – reactive oxygen species; HIF1 – hypoxia-inducible factor 1; VEGF – 
vascular endothelial growth factor.
INTRODUCTION
Pluripotent stem cells are capable both of self-renewal 
and generation of all the cell types that constitute the 
three germ layers. until recently, pluripotent stem cells 
were derived from cultures obtained from the inter-
nal cell mass of the blastocyst (embryonic stem cells – 
eScs) [1, 2]. However, the procedure of obtaining eScs 
was burdened with numerous practical and ethical 
issues that made it impossible to use eScs in clinical 
practice. Because of this, the global scientific commu-
nity pressed on with its active search for an appro-
priate method for obtaining cells with characteristics 
similar to those of eScs. certain progress was achieved 
in 1997, when Wilmut et al. reprogrammed breast so-
matic cells via the transfer of their nuclei into oocytes 
after the second meiotic division (somatic cell nuclear 
transfer, Scnt) [3–6]. In 2001, tada et al. achieved the 
same result via the fusion of mouse thymocytes with 
eScs [7]. However, all attempts aimed at eliminating 
the technical complexity and low reproducibility of 
these methods failed, as did the attempts aimed at us-
ing these techniques for primate cells.
In 2006, based on accumulated data, takahashi 
and Yamanaka assumed that an unfertilized cell and 
eScs contain pluripotency-determining factors [8]. 
the method for the introduction of genes playing a key 
role in early development using lentiviral constructs 
was described in their studies on mouse fibroblasts [8] 
and, subsequently, on human cells [9]. It was success-
fully demonstrated that the ectopic gene expression of 
only four transcriptions factors, Oct4, Sox2, Klf4, and 
c-Myc (subsequently referred to as the KMOS canoni-
cal gene set, or the “Yamanaka cocktail”), is sufficient 
for the reprogramming of fibroblasts into a pluripo-
tent state. the cells obtained using this procedure were 
referred to as induced pluripotent stem cells (iPScs); 
the phenomenon of reprogramming into a pluripotent 
state was referred to as induced pluripotency. Many 
characteristics of iPScs are identical to those of eScs 
(e.g., gene expression profiles, morphology, telomerase 
activity, the character of DnA methylation and his-
tone modification). Furthermore, iPScs are capable of 
in vitro generation of the tissue cells of the three germ 
layers; they form mature teratomas after they are in-
jected into immunodeficient mice. chimeric animals 
were successfully created; their descendants included 
the ones obtained from the reprogrammed cells [10, 11]. 
At the time of writing, a significant number of stud-
ies have been published reporting that human iPScs 
have been obtained via various methods [12]. cell re-
programming techniques characterized by higher effi-
ciency and safety compared to the transfection of viral reVIeWS
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vectors have been designed for potential clinical use 
[13]. iPScs from patients with various inherited diseas-
es have been obtained [13, 14]. there are two extensive 
research areas associated with cell reprogramming: 
namely, fundamental research of cell plasticity and the 
genetic mechanisms underlying the early development 
of the organism and neoplasias, and the technologies 
for reprogramming somatic cells in order to conduct 
substitution cell therapy [15]. the cell technologies 
using iPScs are capable of providing patient-specific 
cell lines, including those obtained from the carriers 
of inherited diseases. these cell lines can be used for 
the simulation of various diseases and for the testing of 
new pharmaceutical agents.
 
MOLECULAR MECHANISMS UNDERLYING 
PLURIPOTENCY INDUCTION
Autoregulatory loop. The equilibrium between 
Klf4 and c-Myc. The impact of the Ink4/Arf locus
A trove of data has been published to support the hy-
pothesis that pluripotency is regulated by three tran-
scription factors, Oct4, Sox2, and nanog [16]. It was 
demonstrated [17, 18] that the combination of Oct4, 
Sox2, and nanog factors activates the promoters of 
both their own genes and the genes of each other, thus 
forming an autoregulatory loop. Data exists indicating 
that the autoregulatory loop enhances the stability of 
the pluripotency gene expression [19, 20]. the three 
factors under consideration are also capable of initiat-
ing the cascades of both active and inactive genes (in-
volving up to several hundreds of them). the expres-
sion of the Oct4, Sox2, and Nanog genes serves as the 
basis for the transcriptional network, which ensures 
the pluripotency of eScs by enhancing pluripotency 
gene transcription and simultaneously suppressing the 
activity of the genes associated with the differentiation 
and development [21–23].
In their pioneering studies, takahashi and Ya-
manaka proceeded with the analysis of 24 genes and 
subsequently elucidated that four genes (Oct4, Sox2, 
Klf4 and c-Myc) are sufficient for cell transfer into 
the pluripotent state. Whereas the first two genes are 
pluripotency master genes, the Klf4 and c-Myc genes 
were selected for different reasons. the transcription 
factor с-Myc is known to increase the proliferation rate 
[24], which is an essential condition for successful re-
programming [25]. Moreover, the hyperexpression of 
this gene results in an increase in the p53 protein level. 
It was demonstrated in a number of studies that the 
expression of Klf4 leads to an increase in the level of 
the p21 protein (a cyclin-dependent kinase inhibitor) 
[23] resulting in proliferation suppression, on one hand, 
and reduces the cellular level of p53, which has a posi-
tive effect on the reduction of the apoptosis risk [26], on 
the other hand. thus, one can assume that c-Myc and 
Klf4 are mutually complementary, their action being 
oppositely directed. therefore, equilibrium between 
the expressions of these two genes is important for suc-
cessful reprogramming [27].
the inhibition of the Ink4/Arf locus, which contains 
Cdkn2a and Cdkn2b encoding three powerful tumor 
suppressors, p16 (Ink4a), p19 (Arf), and p15 (Ink4b), is 
one of the key characteristics of pluripotent stem cells. 
It is the Arf gene that activates p53 and p21 in mouse 
cells, whereas the Ink4a gene mostly has these func-
tions in human cells. It was demonstrated [28] that the 
Ink4/Arf locus is completely suppressed both in iP-
Scs and eScs by epigenetic bivalent domain marks 
(the emergence of histone modifications repressing 
H3K27me3); however, the locus can be reactivated 
upon cell differentiation. Oct4, Sox2, and Klf4 jointly 
suppress this locus, increasing both the reprogramming 
kinetics and the number of iPSc colonies, thereby fa-
cilitating the enhanced generation of iPScs. It should 
also be noted that some researchers directly attribute 
the activation of the Ink4/Arf locus to the overall ag-
ing of the organism. therefore, it is more difficult to re-
program cells taken from an old donor in comparison to 
those taken from a young one. In this case, the suppres-
sion of the Ink4/Arf locus can considerably increase 
the efficiency and rate of reprogramming [25].
 
Epigenetic regulation of gene expression 
in pluripotent stem cells
eScs can be distinguished from the differentiated cells 
due to certain epigenetic characteristics. thus, the key 
pluripotency genes (Oct4 and Nanog) are demethylated 
in eScs and can be actively transcribed, whereas the 
differentiation results in the suppression of these genes 
via de novo DnA methylation. It is of interest that the 
methylation marks are removed during reprogramming. 
this enables the reactivation of the endogenous tran-
scription of these genes [29].
In addition to DnA methylation, eScs and the dif-
ferentiated cells also have different histone modification 
patterns. thus, the suppression of the genes responsible 
for the development and differentiation of eScs is regu-
lated via combinations of the activation (H3K4me3) and 
repression (H3K27me3) of histone modifications. tran-
scription regulation is mediated by Polycomb-group 
proteins, which suppress gene expression by means of 
their binding to the histones containing H3K27me3. 
this mechanism is considered to be a tool for the tran-
scriptional flexibility of eScs, which is conditioned by 
stable repression of the development-associated genes 
without the irreversible inactivation of these genes. 
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be found virtually only in eScs and are an important 
characteristic of the pluripotent status, one can assume 
that the regeneration of “bivalent domains” is also a 
key stage in the reprogramming of somatic cells in iP-
Scs. It has been demonstrated in a number of studies 
that chromatin in the completely reprogrammed iPScs 
contains bivalent histones that are identical to those in 
eScs [10, 30].
At the time of writing, neither study completely rep-
resents the picture of the relationship between the tran-
scription factors, chromatin modifications, and cascades 
of pluripotency genes during cell reprogramming. nev-
ertheless, not much data has been published relating to 
the analysis of the expression of transcription factors in 
human and mouse eScs [31] and in iPScs [32], which 
can be used as a basis to construct the reprogramming 
model. Based on the data available, one can assume that 
Oct4, Sox2, nanog, and Klf4 are the key units of the 
reprogramming process, during which nucleosome 
recovery, assemblage of diacetylases, activation of 
Polycomb proteins, and chromatin remodeling occur. 
In 2010, Pereira et al. demonstrated in their studies de-
voted to the fusion of eScs and lymphocytes that the 
components of the Polycomb complex play a significant 
functional role in epigenetic remodeling. eScs deficient 
in Polycomb-group proteins lost their ability to remodel 
the somatic cell genome [33].
the mechanism underlying the suppression of the 
expression of differentiation genes in pluripotent cells 
comprises the binding of one or several pluripotency 
factors to the target gene promoters [34]. the binding 
between the reprogramming factors and their target 
genes can be facilitated by nucleosome remodeling 
complexes, such as chd1 (chromodomain helicase DnA 
binding protein 1) [35] and BAF (rg/Brahma-associated 
factors – АТР-dependent chromatin-remodeling com-
plex) [36]. these complexes improve the reprogram-
ming efficiency and kinetics. their regulatory role pre-
sumably consists in the reactivation and maintenance 
of the endogenous pluripotency gene expression in the 
absence of exogenous factors. this assumption is based 
on the fact that the endogenous pluripotency signals, 
as well as telomerase and the repressed X-chromosome 
in female cells, are reactivated by the end of the repro-
gramming process, whereas the activity of the retrovi-
ral genes is suppressed, although no clearly pronounced 
differentiation and relationship between these proc-
esses have been detected [37].
 
The role of microRNAs in pluripotency maintenance
A considerable improvement in reprogramming effi-
ciency after the Lin28 gene is added to the set of re-
programming factors has been observed in a number 
of studies devoted to the reprogramming of somatic 
cells to a pluripotent state [38]. the major contribution 
of the Lin28 gene is thought to be its participation in 
micrornA (mirnA) processing. It was assumed that 
in eScs, Lin28 inhibits let7 mirnA processing [39], a 
well-known tumor growth suppressor gene. this gene 
participates in the suppression of c-Myc activity. Fur-
thermore, it was demonstrated that the key repro-
gramming factors Oct4, Sox2, and nanog are capable 
of initiating the mir-90 family, whose members are 
expressed in eScs under normal conditions and partici-
pate in the proliferation regulation, as well as the self-
maintenance, of these cells. the activation of mir-290 
during reprogramming may also be a result of chro-
matin remodeling by c-Myc [40]. the mirnA cluster 
(mir-203–367) promoter is one of the targets of the 
pluripotency transcription factors Oct4, Sox2, nanog, 
and rex1. Its products can indirectly induce tGF-β/
nodal/Activin signaling pathways (this signaling path-
way plays a significant role in the maintenance of the 
pluripotency status of eScs and in the suppression of 
their differentiation) by inhibiting some pathway regu-
lators, which in turn has a positive effect on the main-
tenance of cells in an undifferentiated state.
 
The effect of cell aging and 
immortalization on reprogramming
Studies devoted to the interrelationship between re-
programming and the processes of cell aging and im-
mortalization are of considerable interest. It was re-
peatedly reported in the early studies that telomerase 
activity increases in somatic cells and telomeric DnA 
regions last considerably longer in the course of re-
programming. thus, the reprogrammed cells acquire 
immortality, typical of eScs [8, 9, 41]. Yehezkel et al. 
[42] thoroughly studied the telomere length, the meth-
ylation in subtelomeric regions, and expression of the 
telomeric-repeat-containing rnA (referred to as ter-
rA) in iPScs. In addition to supporting the previously 
ascertained data regarding telomerase activation and 
telomere elongation in iPScs, it was demonstrated that 
subsequent differentiation resulted both in a consider-
able reduction in telomerase expression in the cells un-
der study and in a strong shortening of their telomeric 
regions. the results obtained in that study provided 
evidence in support of the significant role of telomer-
ase and the telomere state in the maintenance of the 
pluripotent status. the subtelomeric regions in iPScs 
were hypermethylated compared with the initial cells, 
whereas the level of terrA was increased relatively. 
It is assumed that regulation of the expression of telo-
meric-repeat-containing rnA can also participate in 
the reprogramming processes, along with regulation of 
the expression of the telomerase catalytic component 
(telomerase reverse transcriptase, tert) [42].reVIeWS
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the essential role of terrA expression in the re-
programming processes was attested to by the results 
of study [43], in which the cells of patients with dysk-
eratosis congenital (a genetic disease associated with 
telomere dysfunction due to premature telomere short-
ening) were investigated. contrary to expectations it 
turned out that the cells reprogrammed via Oct4, Sox2, 
KLf4, and c-Myc also elongate the telomeric regions 
and restore telomerase activity. the mechanism of res-
toration of telomerase activity was attributed to the 
restoration of terrA expression [43].
utikal et al. demonstrated that the acquisition of im-
mortal status is an essential and limiting factor for the 
reprogramming of somatic cells into a pluripotent state, 
which may also attest to the fact that the reprogram-
ming and transformation mechanisms are similar [25].
 
THE COMPLEXITY, MULTISTAGENESS, AND 
STOCHASTICITY OF PLURIPOTENCY INDUCTION
Low reprogramming efficiency is one of the problems 
of cell reprogramming through the addition of tran-
scription factors. In the previous procedure of KMOS 
transfection, approximately 0.01–0.1% of the transfect-
ed cells were subjected to reprogramming; this index 
is considerably lower than that obtained when the cell 
fusion or nuclear transfer technique is used. Several 
hypotheses for explaining such a low yield of repro-
grammed cells have been put forth:
1) iPSc formation requires specifically narrow rang-
es of the expression levels of transcription factors. upon 
simultaneous transfection of several genes within a len-
tiviral construct, the distribution of gene expression 
over cells obeys the probability law (because of differ-
ent viral copy counts per cell and random integration 
into the genome). this is presumably the reason why 
only a small fraction of the transfected cells acquire the 
“proper” set of expression levels of the reprogramming 
factors. the pluripotent status of eScs is known to be 
quite sensitive to the expression levels of pluripotency 
genes; e.g., a 50% variation in the Oct4 expression level 
results in eSc differentiation [44].
2) the populations of reprogrammed somatic cells 
are heterogeneous and contain a certain amount of cells 
that are more susceptible to reprogramming than the 
other cells. For example, some cells (most likely, the di-
viding ones) during the transfection contain chromatin 
in a relatively decondensed state facilitating the repro-
gramming.
3) An unusually high expression level of the exog-
enous reprogramming factors activates the stress-as-
sociated genes that suppress proliferation. thus, the 
expression of the Cdkn1a and Cdkn2a genes, the in-
hibitors of cyclin-dependent kinases that are involved 
in various differentiation pathways, increases in the 
transfected fibroblasts [45]. this fact is explained by 
the addition of transcription factors, since it is already 
known that the Cdkn1a expression is induced by the 
Klf4 factors, whereas Cdkn2a is activated due to the 
aberrant expression of c-Myc [46]. thus, the internal 
self-preservation mechanisms are activated in the 
transfected cells; these mechanisms suppress uncon-
trollable proliferation, finally resulting in a low per-
centage content of cells with a chance of overcoming 
the barrier of proliferation suppression and achieving 
the pluripotent state.
4) Insufficient number of reprogramming factors. 
When using the techniques of reprogramming via cell 
fusion and nuclear transfer, a somatic cell or its nucleus 
is subjected to the action of all the components of the 
pluripotency transcriptional network. these compo-
nents act at all levels, whereas only a limited number 
of factors act on the cells upon reprogramming via len-
tiviral transfection. these factors can activate the tran-
scription cascades only at the very beginning, which 
makes the reprogramming process more vulnerable to 
and dependent on random variations.
Based on these hypotheses, one can conclude that the 
reprogramming induced by the transfection of tran-
scription factors is characterized by a low efficiency 
and multistageness, as well as being strongly depend-
ent upon stochastic processes. the significance of ran-
dom variations upon iPSc formation is supported by 
data showing that the resulting reprogrammed cells are 
appreciably heterogeneous in terms of the general pro-
file of pluripotency gene expression, epigenetic profile, 
and morphology. It was demonstrated that the iPScs 
originating from the same parental cells reactivate the 
expression of endogenous Oct4 at different time points 
during the entire reprogramming process, attesting to 
the multistageness of epigenetic rearrangements and 
the reprogramming in general [27]. However, when 
comparing the reprogramming method under consid-
eration with the previously proposed techniques of nu-
clear transfer and cell fusion, one must allow for the 
fact that the method proposed by takahashi and Ya-
manaka has a number of undeniable advantages, such 
as a relatively low cost and the simplicity of the repro-
gramming technique. the universality of the approach 
should also be noted, since it enables reprogramming of 
human cells, which had previously been impossible.
 
NEW METHODS FOR REPROGRAMMING 
SOMATIC CELLS TO A PLURIPOTENT STATE
the original technique for the transfection of repro-
gramming transcription factors using lentiviral vectors 
has a number of substantial drawbacks that impede its 
application in clinical practice. Virus integration into 
the host genome (up to 20 insertions per reprogram-16 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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ming procedure) increases the risk of tumor formation, 
since virus incorporation into the target cell genome 
can accidentally activate or inactivate the host genes, 
thus increasing the mutagenesis risk. continuous trans-
gene overexpression is also problematic because of 
possible incomplete transgene suppression during the 
reprogramming and upon subsequent differentiation. 
even the presence of several pluripotent stem cells in 
the transplanted tissue may result in tumor develop-
ment [47].
One of the strategies to solve these problems is based 
on the reduction of the number of viral vectors intro-
duced, which is achieved via the construction of poly-
cistronic viral vectors carrying several target genes. 
constructs encoding the four major reprogramming 
genes (KMOS) were designed in [47, 48]. the number 
of viral integrations into the genome was successfully 
reduced to 3–5 insertions per cell and the homogene-
ous expression of all four genes in one cell was provided 
via the use of a single lentiviral construction contain-
ing KMOS. Mouse fibroblasts were successfully repro-
grammed via the integration of the polycistronic len-
tiviral vector encoding three genes, Oct4, Sox2, Klf4 
(KOS), followed by the removal of the vector from the 
genome. this approach enhances the attractiveness of 
the method due to the fact that the viral material is 
completely eliminated from the reprogrammed cells 
[49]. A similar procedure was applied in [50]: a spe-
cific piggiBag transposon containing KMOS was used; 
subsequently, it was eliminated to obtain iPScs from 
mouse embryonic fibroblasts, which were free of trans-
genes and vector sequences. this method has also been 
used for human cells in some studies [51]. A consider-
able drawback of the aforementioned approach is that 
the elimination process of a number of transposons fol-
lowing the reprogramming is difficult to control; more-
over, it does not guarantee a 100% result.
the technique for iPSc generation via plasmid 
transfection of the major pluripotency factors (KMOS 
or LnOS – Lin28, Nanog, Oct4, Sox2) based on tempo-
rary expression of the inserted genes was the next ap-
proach in the attempts to resolve the problem of viral 
integration into the genome. Successful application of 
this technique for iPSc generation from various cell 
cultures, including hepatocytes and HeK293 cells, has 
been reported in a number of studies [52–55]. In the 
course of improving the technique, the cells were suc-
cessfully transfected with a single plasmid construct 
encoding the KMOS canonical gene set. this construct 
was eliminated from the cells following the reprogram-
ming [54]. It should be noted that one of the drawbacks 
when using plasmid constructs (compared to the viral 
vector-based methods) is an extremely low reprogram-
ming efficiency, since this method was mostly used to 
generate iPScs from mouse embryonic cells and cell 
lines known for their lability. However, efficiency in 
reprogramming human fibroblasts was enhanced by 
1% by using riP/eBnA1 episomal plasmid vectors that 
can encode six genes (Oct4, Sox2, Klf4, c-Myc, Lin28, 
and Nanog) at once [56].
Another unavoidable drawback of the techniques 
based on plasmid vectors is the possibility that residual 
DnA vectors may be present in the target cells after the 
reprogramming, and therefore the theoretical possibil-
ity of insertion mutagenesis [56]. Several methods were 
designed while searching for approaches that would 
eliminate the possibility of the incorporation of foreign 
DnA into the host DnA. Human iPScs were generated 
using the Sendai transgenic virus with a reproductive 
cycle based only on rnAs, which contains neither the 
stage of DnA reverse transcription (as is the case in len-
tiviral vectors) nor the stage of integration into the host 
genome [57]. the advantage of this method is the rela-
tively high gene introduction into various cells and tis-
sues; the drawbacks include the complicated handling of 
the Sendai virus and the compulsory purification of the 
reprogrammed cell to remove the replicating virus [57].
Another reprogramming approach without the use 
of DnA vectors is based on the delivery of reprogram-
ming factor proteins directly into the cells. A specific 
complex of recombinant proteins consisting of the pol-
yarginine protein-transducing subunit bound to all four 
major reprogramming factors (KMOS) was designed 
to create proteins capable of penetrating through the 
plasma membrane of somatic cells [58]. this approach is 
relatively simple; the risk of changes in the target cells 
caused by exogenous genetic sequences decreases when 
using this technique [58]. However, in a later study in 
which human cells were used as an object [59], low ef-
ficiency was reported for the method. the efficiency 
of reprogramming using KMOS proteins conjugated 
to the cell-penetrating peptide (cPP), which contains a 
large percentage of basic amino acids and is capable of 
penetrating through the cell membrane, was equal to 
0.001%, which is lower than that in the methods based 
on viral integration by two orders of magnitude.
transfection of the in vitro synthesized mrnA of 
transcription factors is another promising method for 
reprogramming somatic cells without the use of DnA 
vectors. the researchers used mrnA of the LnOS 
genes [60] to successfully reprogram human neonatal 
fibroblasts to a pluripotent state. However, despite the 
fact that the result was achieved, a low reprogramming 
efficiency (0.0005%) was also observed. the authors at-
tributed this problem to the high cytotoxicity of large 
mrnA doses [60]. However, the difficulties were over-
come via the use of synthetic mrnA of the KMOS and 
Lin28 genes, which was comprised of modified ribonu-reVIeWS
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cleotides [61]. combined with the use of the interferon 
inhibitor B18r and cell culturing under low oxygen 
content, this technique enabled the attainment of low 
cytotoxicity and transfection. thanks to these modifi-
cations, the reprogramming efficiency increased by two 
orders of magnitude and reached 4.4% compared with 
the 0.04% that was obtained using viral transfection. A 
large-scale research project focused on the reprogram-
ming of a wide range of somatic cells (including human 
cells) and analysis of the resulting iPScs was subse-
quently carried out [61].
 
THE USE OF SMALL MOLECULES FOR REPROGRAMMING
the use of low-molecular-weight compounds, the so-
called small reprogramming molecules, is one of the ap-
proaches to the reprogramming of human somatic cells. 
combined with the earlier designed methods, these 
molecules are capable of either functional substitution 
of particular reprogramming factors or facilitating the 
increase in efficiency of the process. thus, BIX-01294 
(BIX), an inhibitor for the G9a histone methyltrans-
ferase, was used. the application of this agent in ad-
dition to the transfection using the Klf4, c-Myc, and 
Sox2, as well as the Klf4 and Oсt4 sets within the len-
tiviral vectors, considerably enhanced (by a factor of 
6–10) the yield of the reprogrammed cells [45]. this is 
attributed to the specific activity of BIX, which facili-
tates chromatin de-condensing and therefore can func-
tionally substitute the c-Myc transcription factor [45]. 
2-propylvaleric acid (valproic acid, VPA) is another 
compound capable of considerably increasing the re-
programming efficiency [62]. It can specifically inhibit 
DnA methyltransferases and histone deacetylase. Ac-
cording to [38], the use of this small molecule, in addi-
tion to the standard KMOS set, enhances the repro-
gramming efficiency by 1–2 orders of magnitude and 
allows one to dispense with the c-Myc oncogene. the 
positive effect of 5-azacytidine (5-azac) on the yield of 
reprogrammed cells was demonstrated using the same 
strategy for DnA methyltransferase inhibition [29]. re-
programming efficiency can also be increased via the 
introduction of a small interfering rnA (sirnA), which 
inhibits the transcripts of the commitment-associated 
genes [29]. the positive effect of cHIr99021, a specific 
inhibitor of glycogen synthase kinase 3 (GSK-3), on 
efficiency in the reprogramming of mouse embryonic 
fibroblasts has been described. the yield of iPSc colo-
nies was considerably increased by using cHIr99021. 
the number of reprogramming factors was reduced to 
two, Klf4 and Oct4, thanks to the use of this reagent in 
a number of experiments [63].
Small molecules, such as arginine methyltrans-
ferase inhibitor AMI-5 and transforming growth fac-
tor β inhibitor A-83-01, facilitate the reprogramming 
process [64]. the induction of mouse fibroblasts by 
Oct4 only and the addition of the two aforementioned 
small compounds resulted in the generation of iPScs 
that expressed the typical pluripotency markers and 
could be differentiated into cells of three germ layers 
and produce viable chimeric mice. AMI-5 activity is 
comparable to the joint effect of three components 
(cHIr99021, Parnate and VPA). AMI-5 inhibits the 
activity of PrMt 1/3/4/6 and belongs to the fam-
ily of proteins that catalyze mono- or dimethylated 
arginine residues. However, it remains to be deter-
mined how AMI enhances Oct-4-induced cell pro-
gramming.
Interesting results were obtained when studying the 
effect of vitamin c on iPSc generation [65]. It turned 
out that the treatment of cells undergoing reprogram-
ming with vitamin c in combination with the activation 
of the Klf4, c-Myc, and Oct4 genes resulted in a con-
siderable decrease in the p53 and p21 levels, as well as 
in the concentration of reactive oxygen species (rOS). 
It has been assumed that this factor enhances the re-
programming efficiency, since an increase in the rOS 
level is usually observed upon transfection with viral 
vectors. Sodium butyrate has a positive effect on the 
generation of iPScs from adult and embryonic human 
fibroblasts [51]. It is suggested that sodium dutytate 
promotes the expression of DnA demethylase and H3 
acetylation, which ultimately facilitates the expression 
of endogenous pluripotency factors, including Oct4 
and Dppa2 (developmental pluripotency associated 2). 
the screening of various low-molecular-weight com-
pounds was performed in one of the recent studies [66] 
focused on the role of small molecules in the processes 
of reprogramming and maintenance of the pluripo-
tent status. A “cocktail” consisting of three molecules, 
PD98059 (mitogen-activated protein kinase inhibitor), 
cHIr99021 (glycogen synthase kinase inhibitor), and 
Y27632 (rho kinase inhibitor), was selected based on 
the results of the study. the cocktail demonstrated a 
considerable effect on the ability of human eScs to 
maintain their undifferentiated state under various 
culturing conditions.
 
DIRECT REPROGRAMMING OF SOMATIC CELLS
the so-called direct reprogramming can be attribut-
ed to areas that require special attention. this strat-
egy presupposes the use of various methods for the 
transdifferentiation of a specialized cell type into an-
other one, bypassing the stage of formation of pluripo-
tent stem cells. If the method for direct reprogramming 
is designed, it would be possible to use cell technologies 
in clinical practice.
Study [67] can be mentioned among such research; in 
the study, mature exocrine cells from mouse pancreas 18 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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were in vivo reprogrammed into β-similar cells using 
adenoviral transcription of the genes of three tran-
scription factors, Ngn3 (Neurog3), Pdx1, and Mafa. the 
morphology, ultrastructure, expression of the major 
markers, and key functions (insulin synthesis) of the 
induced β-cells were identical to those of the intact cells 
[67]. the data on the influence of the Oct4 transcription 
factor on the plasticity of mouse keratinocytes were 
published. Plasmid transfection of the Oct4 gene was 
used to obtain a modified cell culture capable of differ-
entiating into neural lineages under certain culturing 
conditions [68]. this field of research entered its next 
cycle of development in 2010, when it was demonstrat-
ed [69] that a short-term expression of the Oct4 gene is 
sufficient in order to change the direction of differen-
tiation of human keratinocytes, including the neural 
and mesenchymal lineage commitment.
the study where direct reprogramming of embry-
onic and neonatal mouse fibroblasts was induced in vit-
ro [70] is also worthy of mention. A combination of 19 
genes specific for the neural tissue and neurogenesis 
were used to successfully select three genes that per-
form cell transdifferentiation in the neuronal direction.   
retroviruses carrying the Ascl1, Brn2, and Myt1l genes 
were used to infect fibroblast cultures and to observe 
the formation of functional neurons with a complex 
morphology. It also turned out that the formation of 
such characteristics of neural cells as the expression 
of certain neuron-specific voltage-dependent chan-
nel proteins, which are required to generate the action 
potential, can be carried out using a single Ascl1 gene. 
However, joint expression of additional factors is re-
quired to make neuronal cell conversion easier and to 
provide for their complete maturation [70]. A similar 
result was reportedly obtained using human fibroblasts 
[71]: the cell phenotype was changed towards dopamin-
ergic neurons after the Lmx1a and FoxA2 genes were 
additionally inserted into the cells. It was proposed that 
astrocytes be used as an alternative source for the gen-
eration of cells with the characteristics of dopaminergic 
neurons [72].
Despite the apparent complexity related to the 
transdifferentiation of cells derived from one germ lay-
er into cells derived from another germ layer, a number 
of studies have looked into the problem of cell plasticity. 
In these studies, evidence attesting to such a possibility 
was obtained both in vitro and in vivo [73–75].
Soda et al. successfully transdifferentiated  gliob-
lastoma cells into endothelial cells [73]. It was dem-
onstrated that glioblastoma cells can be transdif-
ferentiated into vascular endothelium and produce 
functional blood vessels that are insensitive to the 
inhibition of the VeGF receptor. the results of this 
study attest to the existence of a different mecha-
nism of resistance of glioblastoma cells to anti-
VeGF-therapy. the reprogramming of terminally 
differentiated hepatocytes to neuron-like cells has 
been reported [74].
results of a successful direct reprogramming of 
mouse and human fibroblasts towards the neuronal dif-
ferentiation direction have been published [75]. the re-
programmed cells, in which the expression of the Ascl1 
(Mash1), Nurr1, and Lmx1a genes was induced, were 
very similar to brain dopaminergic neurons in terms of 
the specific protein production, dopamine release, and 
pace-making activity. researchers place their hopes on 
direct reprogramming of one type of cells to dopamin-
ergic neurons that may be usefull in investigating and 
treating some neurodegenerative diseases, such as Par-
kinsons’s disease. 
THE DIFFERENCES BETWEEN iPSCs AND ESCs . 
EPIGENETIC “MEMORY” OF iPSCs
Despite the fact that many characteristics of iPScs 
are rather similar to those of eScs, there are also sig-
nificant differences between these cell types. Among 
others, there are differences in the levels of control 
of pluripotency gene expression and in the formation 
of viable organisms after these cells are transplanted 
into a developing blastocyst to generate chimeric mice. 
evidence has been obtained in support of the fact that 
the methylation levels of cpG islands in eScs and iP-
Scs are similar [76]. A full genome analysis of the cpG 
islands localized in the functional regions compris-
ing more than 14,000 genes revealed the difference 
in the methylation levels of 46 genes. the total cpG 
methylation of the promoter regions in pluripotent 
cells is higher in comparison to that found in somatic 
cells. two eSc and iPSc lines derived from material 
that was genetically identical to eScs were compared 
[77]. In animal chimera experiments, viable mice were 
successfully obtained from two eSc lines, whereas no 
animals were obtained from iPScs. After thorough 
comparison of the rnA transcript profiles, it was as-
certained that the transcription of the imprinted gene 
cluster Dlk1-Dio3 in iPScs is considerably lower than 
that in the eSc lines. It was detected that the region 
on chromosome 12 containing the key genes for fetal 
development was silenced in the iPSc line. Over 60 iP-
Sc-like cell lines were also tested; a similar result was 
observed in most cases. It should be noted that this 
gene cluster was activated in a number of iPSc lines. 
chimeric living mice were subsequently obtained 
from these cell lines. thus, the state of this imprinted 
cluster allows one to introduce another characteristic 
for the adequacy of iPSc reprogramming [77]. iPScs 
can be differentiated into definitive endoderm pre-
cursor cells to design approaches to the cell therapy of reVIeWS
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damaged tissues of endodermal origin despite the fact 
that there are some differences between them at the 
molecular level [78].
It has been assumed that in addition to their poten-
tial application for the purpose of regenerative medi-
cine, human eScs and iPScs can be used to simulate 
human inherited disorders. Meanwhile, before using 
these cells as a model for a particular disease, one needs 
to assess whether they contain any chromosomal re-
arrangements, which have put limits on the applica-
tion of reprogrammed cells. Significant differences be-
tween the chromosomal characteristics of iPScs and 
eScs have been revealed [79]. iPScs were obtained 
from the skin cells of three patients with a fragile X 
syndrome (FX) that is responsible for delayed men-
tal development. unlike eScs obtained from patients 
with the FX syndrome, FMR1 gene expression in cer-
tain types of differentiated cells from the same patients 
was reduced due to anomalous duplications of triplet 
repeats. It was demonstrated that iPScs contain a mu-
tated FMR1 gene, which was not changed in the course 
of reprogramming, despite the pluripotent status [80]. 
the study made it apparent that iPScs are not always 
suitable candidates for the simulation of diseases as-
sociated with epigenetic changes, including imprint-
ing. In a similar study [81], DnA methylation patterns 
were analyzed in the genomes of 15 cell lines (four eSc 
lines, five human iPSc lines and the tissues from which 
these iPScs were derived, and the differentiated cells 
obtained from the aforementioned two stem cell lines). 
Significant differences between iPScs and eScs were 
revealed; the methylation patterns near the chromo-
some ends and centres of iPScs remained identical to 
those in the differentiated cells from which they were 
obtained. It is clear that reprogramming is a means for 
acquiring a pluripotent status other than obtaining 
cells from the embryos. relying on these data, one can 
conclude that formation of certain cell types from re-
programmed cells may be restricted. the fact that re-
programmed stem cells have an epigenetic “memory” 
agrees with the recently published results of a com-
parison of iPScs, eScs, and pluripotent mouse cells ob-
tained using the nuclear transfer procedure [82]. It was 
demonstrated that iPScs contain residual epigenetic 
marks; however, these marks can be eliminated upon 
continuous culturing or by using specific agents that 
rearrange the chromatin structure. It was also ascer-
tained that pluripotent stem cells obtained by nuclear 
transfer reprogram the epigenetic profile more effi-
ciently in comparison with iPScs.
In addition to the epigenetic “memory,” the exist-
ence of gene duplications or deletions associated with 
genomic instability is the significant comparative char-
acteristic of iPScs. Genotyping of single nucleotide 
substitutions was used to compare 69 eSc lines and 37 
iPSc lines between, as well as with linear and primary 
human cell cultures [83]. the results of this thorough 
study attest to the fact that pluripotent cells in general 
(and iPScs to a larger extent) tend to accumulate dupli-
cations in the genomic regions containing the pluripo-
tency genes and oncogenes, as well as to accumulate 
deletions in the region containing tumor growth sup-
pressing genes.
Many researchers attribute the differences between 
iPScs and eScs to the reprogramming procedure and 
the existence of viral insertions into the genome. the 
transcription profiles of human eScs and iPScs were 
compared using methods without the use of viral con-
structs [84]. the transcription profiles of eScs and iP-
Scs were shown to be largely similar; however, some 
differences were detected, which cannot be attributed 
to viral integration into the genome.
 
THE POTENTIAL OF USING iPSCs IN CLINICAL PRACTICE
Allogenic organ transplantation is associated with 
a number of problems, such as limited tissue engraft-
ment and the necessity to use immunosuppressors. It is 
believed that these problems can be overcome by re-
programming the patient’s own cells, because the cells 
grafted to the recipient will be genetically identical to 
his own cells. the method proposed is undoubtedly su-
perior to the existing transplantation techniques be-
cause of the possibility of in vitro study and repair of 
the pathological mutations in the cells. For example, 
sicklemia has been successfully repaired using iPScs on 
a mouse model [85]. the formation of normal erythro-
cytes from hematopoietic precursor cells obtained from 
completely reprogrammed skin cells was observed in 
[85].
Many diseases, such as diabetes mellitus type 1, the 
Parkinson’s and Alzheimer’s diseases, etc. are very 
difficult to study and cure both because the damaged 
organ is difficult to reach (hence the difficulties associ-
ated with the search for donor tissue) and because no 
methods have been designed for the continuous cultiva-
tion of the proper cell lines. When simulating these dis-
orders, autological iPScs can be obtained, followed by 
their differentiation in a culture into the required cell 
line to produce adequate test systems for the screen-
ing of pharmaceutical agents. these test systems can 
also be used to investigate the diseases accompanied by 
pathological motoneuronal death (e.g., in patients with 
amyotrophic lateral sclerosis or spinal muscular amyo-
trophy). the lack of cell materials originating from 
patients at late stages of the development of a disease 
is one of the main problems associated with the study 
of degenerative pathologies. Since iPScs presumably 
have to undergo all the differentiation stages in vitro, 20 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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same as the recipient’s cells before the disease develops 
in vivo, this technology can make it possible to study 
the early stages of a particular disease. Active research 
has been carried out; iPScs have been already obtained 
in some laboratories from patients with Hungtington’s 
disease, sicklemia, myodystrophy, the Down’s syn-
drome, etc. [13, 14, 86, 87].
considerable differences between the same cell 
types differentiated from eScs and iPScs have been 
revealed [88]. Study of teratoma formation in c57BL/6 
and 129/SvJ mice has demonstrated that the disrup-
tion of gene expression in some cells differentiated 
from iPScs may result in a t cell-dependent immune 
response in an isogenic recipient. thus, the currently 
available reprogramming technologies are still a long 
way from clinical application. One of the primary tasks 
consists in the design of methods that would enable the 
epigenetic differences between iPScs and eScs to be 
minimized.
 
APPROACHES TO THE CLINICAL USE OF iPSCs
the use of oncogenes to obtain iPScs is one of the ma-
jor problems impeding the therapeutical use of these 
cells. the с-Myc oncogene is hyperexpressed in ap-
proximately 70% of human tumors; therefore, the hy-
perexpression of an inserted transgene makes the use 
of iPScs dangerous [89]. In order to solve this problem, 
iPScs obtained from humans and mice were subject-
ed to study. no postnatal tumor development was ob-
served in chimeric mice obtained from iPScs without 
introduction of c-Myc, whereas oncological diseases 
developed in ~15% of the animals obtained from iP-
Scs with exogenous c-Myc [90]. Oct4, Sox2, and Klf4 
can also be associated with the emergence of different 
types of tumors; therefore, researchers increasingly try 
to avoid the transduction of these oncogenes [54, 56, 
61, 91]. In order to achieve the necessary results, tar-
get cells are selected that would endogenously express 
the required factor at an adequate level, hence its in-
troduction would be rendered unnecessary. thus, the 
endogenous Sox2 gene is strongly expressed in neutral 
stem cells; these cells were successfully reprogrammed 
in a number of experiments by inserting Oct4 and Klf4 
only [45, 92] or even Oct4 alone [92, 93]. Meningiocytes 
and keratinocytes can be regarded as promising cells 
for reprogramming because of their relatively high lev-
els of Sox2 [94], c-Myc, and Klf4 [95, 96] expression. It 
has also been discovered that it is easier to derive iP-
Scs from amniotic fluid cells because of the fact that 
they are relatively weakly differentiated [97, 98]. the 
rate of iPSc formation from amniotic fluid cells is at 
least twice faster than that of iPSc formation from fi-
broblasts, whereas the reprogramming efficiency in 
the former case is higher by an order of magnitude. 
One of the approaches to reprogramming consists in 
the replacement of oncogenes for small molecules [38, 
45]. teratogenicity of iPScs is a significant issue, since 
there may remain a certain amount of undifferenti-
ated iPScs that are dangerous for the recipient after 
these cells are differentiated into the specialized cells 
intended for transplantation [99]. the search for selec-
tion methods that would ensure the isolation of iPScs 
from the differentiated cells continues. the karyotypic 
instability of pluripotent cell lines has been revealed via 
the study of the chromosome composition of eScs and 
iPScs [100], attesting to the necessity for a thorough 
cytogenetic analysis of iPScs and initial cell lines.
the similarities and differences between eScs and 
iPScs are being actively investigated at the molecu-
lar and functional levels. the results of these studies 
may influence the therapeutic applicability of iPScs. 
this field of research (as well as the development and 
optimization of differentiation protocols and the es-
tablishment of reliable criteria for the application of 
specialized cells generated from iPScs) requires an 
analysis of the genomic and epigenomic statuses of 
human iPScs. 
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